Research programme: antibody drug conjugates - Glykos/Orion
Latest Information Update: 30 Jan 2024
At a glance
- Originator Glykos
- Developer Glykos; Orion
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 11 Jan 2024 Early research in Solid tumours in Finland (Parenteral)
- 08 Jan 2024 Orion Corporation in-licenses antibody-drug conjugates from Glykos